Application value of CT radiomic nomogram in predicting T790M mutation of lung adenocarcinoma

被引:3
|
作者
Li, Xiumei [1 ]
Chen, Jianwei [2 ]
Zhang, Chengxiu [3 ]
Han, Zewen [1 ]
Zheng, Xiuying [1 ]
Cao, Dairong [1 ,4 ,5 ,6 ]
机构
[1] Fujian Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Fuzhou 350005, Fujian, Peoples R China
[2] Fujian Prov Canc Hosp, Dept Pathol, Fuzhou 350014, Fujian, Peoples R China
[3] East China Normal Univ, Sch Phys & Elect Sci, Shanghai Key Lab Magnet Resonance, Shanghai 200062, Peoples R China
[4] Fujian Med Univ, Affiliated Hosp 1, Natl Reg Med Ctr, Dept Radiol, Binhai Campus, Fuzhou 350212, Fujian, Peoples R China
[5] Fujian Med Univ, Affiliated Hosp 1, Fujian Key Lab Precis Med Canc, Fuzhou 350005, Fujian, Peoples R China
[6] Fujian Med Univ, Affiliated Hosp 1, Key Lab Radiat Biol, Fujian Higher Educ Inst, Fuzhou 200062, Peoples R China
关键词
Lung adenocarcinoma; Radiomics; Computed tomography; T790M; CANCER;
D O I
10.1186/s12890-023-02609-y
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
BackgroundThe purpose of this study was to develop a radiomic nomogram to predict T790M mutation of lung adenocarcinoma base on non-enhanced CT lung images.MethodsThis retrospective study reviewed demographic data and lung CT images of 215 lung adenocarcinoma patients with T790M gene test results. 215 patients (including 52 positive) were divided into a training set (n = 150, 36 positive) and an independent test set (n = 65, 16 positive). Multivariate logistic regression was used to select demographic data and CT semantic features to build clinical model. We extracted quantitative features from the volume of interest (VOI) of the lesion, and developed the radiomic model with different feature selection algorithms and classifiers. The models were trained by a 5-fold cross validation strategy on the training set and assessed on the test set. ROC was used to estimate the performance of the clinical model, radiomic model, and merged nomogram.ResultsThree demographic features (gender, smoking, emphysema) and ten radiomic features (Kruskal-Wallis as selection algorithm, LASSO Logistic Regression as classifier) were determined to build the models. The AUC of the clinical model, radiomic model, and nomogram in the test set were 0.742(95%CI, 0.619-0.843), 0.810(95%CI, 0.696-0.907), 0.841(95%CI, 0.743-0.938), respectively. The predictive efficacy of the nomogram was better than the clinical model (p = 0.042). The nomogram predicted T790M mutation with cutoff value was 0.69 and the score was above 130.ConclusionThe nomogram developed in this study is a non-invasive, convenient, and economical method for predicting T790M mutation of lung adenocarcinoma, which has a good prospect for clinical application.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
    Zhao, S.
    Jiang, T.
    Li, X.
    Zhao, C.
    Su, C.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S410 - S410
  • [42] The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
    Tseng, Jeng-Sen
    Su, Kang-Yi
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Chen, Hsuan-Yu
    Tsai, Chi-Ren
    Yu, Sung-Liang
    Chang, Gee-Chen
    ONCOTARGET, 2016, 7 (30) : 48059 - 48069
  • [43] Detection of low-level EGFR T790M mutation in lung cancer tissues
    Oh, Ji Eun
    An, Chang Hyeok
    Yoo, Nam Jin
    Lee, Sug Hyung
    APMIS, 2011, 119 (07) : 403 - 411
  • [44] Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review
    Yamaguchi, Fumihiro
    Kato, Eisuke
    Wakabayashi, Aya
    Shikama, Yusuke
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (02) : 127 - 131
  • [45] Osimertinib shows promise in treating choroidal metastases and improving vision in EGFR T790M mutation-positive lung adenocarcinoma
    Keshwani, K.
    Roelofs, K.
    Hay, G.
    Lewis, R.
    Plowman, P.
    LUNG CANCER, 2020, 139 : S94 - S94
  • [46] The analytical sensitivity for detecting T790M mutation in circulating tumour DNA of lung adenocarcinoma patients. Comparison of two methodologies
    Fahoum, I.
    Hershkovitz, D.
    Forer, R.
    Volodarsky, D.
    Bick, T.
    Sarji, S.
    Ben-Izhak, O.
    Vulih, I.
    VIRCHOWS ARCHIV, 2017, 471 : S166 - S167
  • [47] Origin of the T790M mutation and its impact on the clinical outcomes of I patients with lung adenocarcinoma receiving EGFR-TKIs
    Dong, Yujie
    Zhou, Zhen
    Wang, Jianguo
    Ma, Li
    Liu, Zichen
    Wang, Yuxuan
    Song, Jing
    Zhang, Shucai
    Che, Nanying
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (05) : 946 - 951
  • [48] Is T790M Mutation A "Regulator" for EGFR Signal Pathway Not an Oncogene?
    Wang, Zheng
    Liu, Dongge
    Shi, Yuankai
    Han, Xiaohong
    Tong, Hongfeng
    Wu, Qingjun
    Zhang, Jianguang
    Wang, Tianyang
    Cram, David
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S487 - S487
  • [49] PREDICTIVE FACTORS OF OSIMERTINIB AS SALVAGE TREATMENT FOR METASTATIC EGFR T790M POSITIVE LUNG ADENOCARCINOMA
    Park, Ji Young
    Jang, Seung Hun
    Kim, Hwan Il
    Kim, Joo-Hee
    Park, Sunghoon
    Hwang, Yong Il
    Jung, Ki-Suck
    Seo, Jinwon
    RESPIROLOGY, 2019, 24 : 177 - 177
  • [50] Liquid biopsy for T790M mutation detection: A ray of hope?
    Mohan, Anant
    Mittal, Saurabh
    LUNG INDIA, 2020, 37 (01) : 1 - 2